Clazakizumab: Difference between revisions
Content deleted Content added
compound is not yet being marketed; separate history section unecessary |
mNo edit summary |
||
| Line 35: | Line 35: | ||
}} |
}} |
||
'''Clazakizumab''' (formerly ALD518 and BMS-945429),<ref name=Claz-2B>[http://news.bms.com/press-release/financial-news/promising-phase-iib-data-clazakizumab-patients-moderate-severe-rheumato Promising Phase IIb Data On Clazakizumab In Patients With Moderate-To-Severe Rheumatoid Arthritis To Be Presented At The 2013 Annual Meeting Of The American College Of Rheumatology ]</ref> and [[investigational drug]], is a [[aglycosylated]], humanized [[monoclonal antibody]] against [[interleukin-6]]. |
'''Clazakizumab''' (formerly ALD518 and BMS-945429),<ref name=Claz-2B>[http://news.bms.com/press-release/financial-news/promising-phase-iib-data-clazakizumab-patients-moderate-severe-rheumato Promising Phase IIb Data On Clazakizumab In Patients With Moderate-To-Severe Rheumatoid Arthritis To Be Presented At The 2013 Annual Meeting Of The American College Of Rheumatology ]</ref> and [[investigational drug]], is a [[aglycosylated]], humanized [[monoclonal antibody]] against [[interleukin-6]]. Clazakizumab was developed by [[Alder Biopharmaceuticals]] and licensed to Vitaeris, Inc.<ref>https://globenewswire.com/news-release/2016/07/26/859067/0/en/Alder-BioPharmaceuticals-Reports-Second-Quarter-2016-Financial-and-Operating-Results.html</ref> |
||
==See also== |
==See also== |
||
Revision as of 22:14, 23 January 2017
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL6 |
| Clinical data | |
| Routes of administration | infusion |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| Chemical and physical data | |
| Formula | C6426H9972N1724O2032S42 |
| Molar mass | 145.2 kg/mol g·mol−1 |
Clazakizumab (formerly ALD518 and BMS-945429),[1] and investigational drug, is a aglycosylated, humanized monoclonal antibody against interleukin-6. Clazakizumab was developed by Alder Biopharmaceuticals and licensed to Vitaeris, Inc.[2]
See also
- Tocilizumab (Actemra) an anti-IL-6 receptor mAb
- Anti-IL-6, other anti-interleukin-6 agents
References
- ^ Promising Phase IIb Data On Clazakizumab In Patients With Moderate-To-Severe Rheumatoid Arthritis To Be Presented At The 2013 Annual Meeting Of The American College Of Rheumatology
- ^ https://globenewswire.com/news-release/2016/07/26/859067/0/en/Alder-BioPharmaceuticals-Reports-Second-Quarter-2016-Financial-and-Operating-Results.html
Further reading